6v4t: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==MPER-TMD of HIV-1 Env bound with the entry inhibitor S2C3== | |||
<StructureSection load='6v4t' size='340' side='right'caption='[[6v4t]], [[NMR_Ensembles_of_Models | 14 NMR models]]' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6v4t]] is a 3 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6V4T OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6V4T FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=QOJ:4-[10-(9-azanyl-2,3-dihydro-1~{H}-cyclopenta[b]quinolin-4-yl)decyl]-2,3-dihydro-1~{H}-cyclopenta[b]quinolin-9-amine'>QOJ</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6e8w|6e8w]]</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6v4t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6v4t OCA], [http://pdbe.org/6v4t PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6v4t RCSB], [http://www.ebi.ac.uk/pdbsum/6v4t PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6v4t ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Combination antiretroviral therapy has transformed HIV-1 infection, once a fatal illness, into a manageable chronic condition. Drug resistance, severe side effects and treatment noncompliance bring challenges to combination antiretroviral therapy implementation in clinical settings and indicate the need for additional molecular targets. Here, we have identified several small-molecule fusion inhibitors, guided by a neutralizing antibody, against an extensively studied vaccine target-the membrane proximal external region (MPER) of the HIV-1 envelope spike. These compounds specifically inhibit the HIV-1 envelope-mediated membrane fusion by blocking CD4-induced conformational changes. An NMR structure of one compound complexed with a trimeric MPER construct reveals that the compound partially inserts into a hydrophobic pocket formed exclusively by the MPER residues, thereby stabilizing its prefusion conformation. These results suggest that the MPER is a potential therapeutic target for developing fusion inhibitors and that strategies employing an antibody-guided search for novel therapeutics may be applied to other human diseases. | |||
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.,Xiao T, Frey G, Fu Q, Lavine CL, Scott DA, Seaman MS, Chou JJ, Chen B Nat Chem Biol. 2020 Mar 9. pii: 10.1038/s41589-020-0496-y. doi:, 10.1038/s41589-020-0496-y. PMID:32152540<ref>PMID:32152540</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6v4t" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Chen, B]] | |||
[[Category: Chou, J J]] | |||
[[Category: Frey, G]] | |||
[[Category: Fu, Q]] | [[Category: Fu, Q]] | ||
[[Category: Lavine, C L]] | |||
[[Category: Scott, D A]] | |||
[[Category: Seaman, M S]] | |||
[[Category: Xiao, T]] | [[Category: Xiao, T]] | ||
[[Category: | [[Category: Entry inhibitor]] | ||
[[Category: | [[Category: Hiv-1 env]] | ||
[[Category: | [[Category: Mper]] | ||
[[Category: | [[Category: Small-molecule]] | ||
[[Category: | [[Category: Viral protein]] | ||